Wilson Lin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Wilson Lin has a total of 70 co-authors. Here are the top co-authors by number of shared publications:
- Jonathan W. Engle
University of Wisconsin−Madison
14 shared publications - Eduardo Aluicio-Sarduy
Department of Medical Physics, University of Wisconsin-Madison, Madison, WI, 53705, USA
13 shared publications - Aeli P. Olson
University of Wisconsin–Madison, United States
11 shared publications - Amanda G. Shea
Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison, Madison, USA
11 shared publications - Amber M. Bates
Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI 53705, USA
11 shared publications - Anatoly N. Pinchuk
University of Wisconsin–Madison, Madison, WI, United States
11 shared publications
Latest Publications
- Open Access
- 9 July 2026
- Published by Elsevier in Physics Letters B
- Vol. 880
Using Neural Networks to Accelerate TALYS-2.0 Nuclear Reaction Simulations
- 9 July 2026
- Published by Elsevier in Physics Letters B
- Vol. 880
Open AccessUsing Neural Networks to Accelerate TALYS-2.0 Nuclear Reaction Simulations
- Open Access
- 10 December 2025
- Published by Springer Nature in EJNMMI Radiopharmacy and Chemistry
- Vol. 10 (1) , 78
Establishing Pb-203 production from electrodeposited Tl targets at Brookhaven National Laboratory
Background: Promising developments in Pb-212 radiopharmaceutical therapies have increased demand for Pb-203 diagnostic agents. Building on previous work from various isotope production facilities, this study optimized Pb-203 production from electrodeposited Tl targets at Brookhaven National Laboratory (BNL). The additional supply of Pb-203 may help meet growing preclinical and clinical demands. Results: Two Tl targets were irradiated at the Brookhaven Linac Isotope Producer facility with 30 ± 1 MeV protons, measured using previously published cross section data. Distribution coefficients for Pb Resin in acetate media were investigated for both Na + and K + cations, where potassium acetate was ~ 4 times more effective at stripping Pb from the Pb Resin. The Tl electrodeposition was optimized to deposit 350 mg of Tl (~ 60 mg/cm 2 ) on Au backing in under 6 h. The proposed separation process was completed in < 1.5 h and achieved > 98% and 92 ± 3% recovery of Tl and Pb, respectively, with an overall Tl-Pb separation factor of 6 × 10 5 . The experimentally measured half-life of Pb-203 was 52.4 ± 0.7 h, agreeing with 51.93 ± 0.02 h reported by the National Nuclear Data Center. The radioisotopic purity of the Pb fraction at 24 h post end of bombardment (EOB) from a 24 h irradiation was 66% Pb-203, 28% Pb-201, and 6% Pb-200. Following chemical separation, the Pb-203 produced in this work (21 MBq Pb-203 EOB) achieved apparent molar activities of 10 ± 5 and 0.9 ± 0.5 GBq/µmol for [ 203 Pb]Pb-DOTAM and [ 203 Pb]Pb-DO3A, respectively, decay corrected to EOB. Data derived from this work suggests BNL can produce > 10’s GBq Pb-203 with > 99% radiochemical and radioisotopic purity from Tl-205 for worldwide distribution. Conclusions: The production and separation of Pb-203 from natural Tl target material was successfully demonstrated at BNL. Existing methods were adapted and optimized for the facilities at BNL. Results from this work will guide future large-scale Pb-203 production opportunities at BNL for clinical applications.
- 10 December 2025
- Published by Springer Nature in EJNMMI Radiopharmacy and Chemistry
- Vol. 10 (1) , 78
Open AccessEstablishing Pb-203 production from electrodeposited Tl targets at Brookhaven National Laboratory
Background: Promising developments in Pb-212 radiopharmaceutical therapies have increased demand for Pb-203 diagnostic agents. Building on previous work from various isotope production facilities, this study optimized Pb-203 production from electrodeposited Tl targets at Brookhaven National Laboratory (BNL). The additional supply of Pb-203 may help meet growing preclinical and clinical demands. Results: Two Tl targets were irradiated at the Brookhaven Linac Isotope Producer facility with 30 ± 1 MeV protons, measured using previously published cross section data. Distribution coefficients for Pb Resin in acetate media were investigated for both Na + and K + cations, where potassium acetate was ~ 4 times more effective at stripping Pb from the Pb Resin. The Tl electrodeposition was optimized to deposit 350 mg of Tl (~ 60 mg/cm 2 ) on Au backing in under 6 h. The proposed separation process was completed in < 1.5 h and achieved > 98% and 92 ± 3% recovery of Tl and Pb, respectively, with an overall Tl-Pb separation factor of 6 × 10 5 . The experimentally measured half-life of Pb-203 was 52.4 ± 0.7 h, agreeing with 51.93 ± 0.02 h reported by the National Nuclear Data Center. The radioisotopic purity of the Pb fraction at 24 h post end of bombardment (EOB) from a 24 h irradiation was 66% Pb-203, 28% Pb-201, and 6% Pb-200. Following chemical separation, the Pb-203 produced in this work (21 MBq Pb-203 EOB) achieved apparent molar activities of 10 ± 5 and 0.9 ± 0.5 GBq/µmol for [ 203 Pb]Pb-DOTAM and [ 203 Pb]Pb-DO3A, respectively, decay corrected to EOB. Data derived from this work suggests BNL can produce > 10’s GBq Pb-203 with > 99% radiochemical and radioisotopic purity from Tl-205 for worldwide distribution. Conclusions: The production and separation of Pb-203 from natural Tl target material was successfully demonstrated at BNL. Existing methods were adapted and optimized for the facilities at BNL. Results from this work will guide future large-scale Pb-203 production opportunities at BNL for clinical applications.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S7 from The Effects of Clinically Relevant Radionuclides on the Activation of an IFN1 Response Correlate with Radionuclide Half-life and Linear Energy Transfer and Influence Radiopharmaceutical Antitumor Efficacy
B78 WT vs. STING KO cell line in vitro Ifnb1 and Ddx58 gene expression upregulation following 225Ac or EBRT.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from The Effects of Clinically Relevant Radionuclides on the Activation of an IFN1 Response Correlate with Radionuclide Half-life and Linear Energy Transfer and Influence Radiopharmaceutical Antitumor Efficacy
B78 WT vs. STING KO cell line in vitro Ifnb1 and Ddx58 gene expression upregulation following 225Ac or EBRT.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S8 from The Effects of Clinically Relevant Radionuclides on the Activation of an IFN1 Response Correlate with Radionuclide Half-life and Linear Energy Transfer and Influence Radiopharmaceutical Antitumor Efficacy
Individual tumor growth curves from Figure 6F.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from The Effects of Clinically Relevant Radionuclides on the Activation of an IFN1 Response Correlate with Radionuclide Half-life and Linear Energy Transfer and Influence Radiopharmaceutical Antitumor Efficacy
Individual tumor growth curves from Figure 6F.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S5 from The Effects of Clinically Relevant Radionuclides on the Activation of an IFN1 Response Correlate with Radionuclide Half-life and Linear Energy Transfer and Influence Radiopharmaceutical Antitumor Efficacy
Longitudinal in vivo gene expression following 12 Gy EBRT (MOC2).
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from The Effects of Clinically Relevant Radionuclides on the Activation of an IFN1 Response Correlate with Radionuclide Half-life and Linear Energy Transfer and Influence Radiopharmaceutical Antitumor Efficacy
Longitudinal in vivo gene expression following 12 Gy EBRT (MOC2).
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S9 from The Effects of Clinically Relevant Radionuclides on the Activation of an IFN1 Response Correlate with Radionuclide Half-life and Linear Energy Transfer and Influence Radiopharmaceutical Antitumor Efficacy
Tumor Ifnb1 expression following 225Ac-NM600+ICI is not affected by loss of STING expression in tumor or host.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S9 from The Effects of Clinically Relevant Radionuclides on the Activation of an IFN1 Response Correlate with Radionuclide Half-life and Linear Energy Transfer and Influence Radiopharmaceutical Antitumor Efficacy
Tumor Ifnb1 expression following 225Ac-NM600+ICI is not affected by loss of STING expression in tumor or host.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S1 from The Effects of Clinically Relevant Radionuclides on the Activation of an IFN1 Response Correlate with Radionuclide Half-life and Linear Energy Transfer and Influence Radiopharmaceutical Antitumor Efficacy
Specific activity maintained in radionuclide-containing cell culture media throughout media exchanges.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from The Effects of Clinically Relevant Radionuclides on the Activation of an IFN1 Response Correlate with Radionuclide Half-life and Linear Energy Transfer and Influence Radiopharmaceutical Antitumor Efficacy
Specific activity maintained in radionuclide-containing cell culture media throughout media exchanges.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Tables from The Effects of Clinically Relevant Radionuclides on the Activation of an IFN1 Response Correlate with Radionuclide Half-life and Linear Energy Transfer and Influence Radiopharmaceutical Antitumor Efficacy
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables from The Effects of Clinically Relevant Radionuclides on the Activation of an IFN1 Response Correlate with Radionuclide Half-life and Linear Energy Transfer and Influence Radiopharmaceutical Antitumor Efficacy
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S4 from The Effects of Clinically Relevant Radionuclides on the Activation of an IFN1 Response Correlate with Radionuclide Half-life and Linear Energy Transfer and Influence Radiopharmaceutical Antitumor Efficacy
Representative images of γH2AX foci over time in (A) MOC2 (12 Gy) and (B) B78 (4 Gy) cells following EBRT, 90Y, 177Lu, and 225Ac.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from The Effects of Clinically Relevant Radionuclides on the Activation of an IFN1 Response Correlate with Radionuclide Half-life and Linear Energy Transfer and Influence Radiopharmaceutical Antitumor Efficacy
Representative images of γH2AX foci over time in (A) MOC2 (12 Gy) and (B) B78 (4 Gy) cells following EBRT, 90Y, 177Lu, and 225Ac.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S2 from The Effects of Clinically Relevant Radionuclides on the Activation of an IFN1 Response Correlate with Radionuclide Half-life and Linear Energy Transfer and Influence Radiopharmaceutical Antitumor Efficacy
Earlier induction of type I IFN response/immunologic response to radiation following 58mCo and 119Sb.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from The Effects of Clinically Relevant Radionuclides on the Activation of an IFN1 Response Correlate with Radionuclide Half-life and Linear Energy Transfer and Influence Radiopharmaceutical Antitumor Efficacy
Earlier induction of type I IFN response/immunologic response to radiation following 58mCo and 119Sb.